SKIBSTED RUSSELL 4

What Happened

CFO Russell Skibsted purchased 3,277 shares of Processa Pharmaceuticals (PCSA) in an open-market transaction on June 30, 2026. The shares were acquired at $1.93 per share for a total transaction value of about $6,325. This was a purchase (insider buy), which some investors view as a modest bullish signal, though the dollar amount is small.

Key Details

• Transaction date: 2026-06-30
• Transaction type/code: Open-market purchase (P)
• Price per share: $1.93
• Shares acquired: 3,277
• Total value: ~$6,325
• Filing date: 2026-07-01 (Form 4 accession 0000897069-26-001478) — appears timely
• Shares owned after transaction: Not specified in the provided filing
• Footnotes/plan: No 10b5-1, gift, or tax-withholding notes listed in the provided details

Context

This is a straightforward open-market purchase by a company executive. The amount is relatively small in dollar terms, so while insider buys can be informative, this single transaction represents a modest personal investment rather than a large-scale insider accumulation. No indications of option exercise, gifts, or other derivative actions were reported.